Navigation Links
IsoPlexis Adds Infectious Disease Pioneer Dr. David Ho to its Scientific Advisory Board
Date:3/14/2017

BRANFORD, Conn., March 14, 2017 /PRNewswire-USNewswire/ -- IsoPlexis Corporation (IsoPlexis), a venture capital-funded life sciences company dedicated to accelerating the fight against cancer, autoimmune disease, infectious disease and more through a precision single-cell detection platform, today announced the appointment of Dr. David Ho to its Scientific Advisory Board. Dr. Ho is a recognized pioneer in the infectious disease area. He has authored more than 400 publications, was named Time magazine's 1996 Man of the Year for his pioneering work in AIDS research and is the recipient of 12 honorary doctorates for his scientific contributions.

IsoPlexis Chief Executive Officer Sean Mackay said, "Dr. David Ho is a critical addition to our Scientific Advisory Board. As we venture into broader applications in infectious disease and beyond, his position as a thought leading scientist will help us to accelerate efforts to combat these diseases."

IsoPlexis Scientific Advisory Board Chair Dr. Rong Fan, an associate professor of Biomedical Engineering at Yale, added, "With Dr. Ho, our scientific board has added a truly eminent scientist with proven success in harnessing the power of immunology to address life-threatening diseases and ailments."

Dr. David Ho is the founding Scientific Director and Chief Executive Officer of the Aaron Diamond AIDS Research Center. His lab helped pioneer the field of quantitation of HIV among infected individuals. In the last decade, his research team extended this work and revolutionized the paradigm for AIDS pathogenesis by demonstrating the highly dynamic nature of HIV replication in vivo. Their groundbreaking studies on HIV dynamics formed the foundation for combination antiretroviral therapy, which Dr. Ho also helped to champion. Such a treatment approach has transformed HIV from a death sentence to a manageable disease, and is now being applied widely throughout the developing world.

Dr. David Ho said, "I am excited to join IsoPlexis as a Scientific Advisory Board member. By merging the top minds in engineering with leading researchers and clinicians, IsoPlexis is able to offer breakthrough clinical insights. As the company's applications expand, it has the potential to make significant progress on critical detection issues, enabling the advancement of various immune therapies."

ABOUT ISOPLEXIS:
IsoPlexis is a life sciences company committed to advancing groundbreaking research and therapeutic development in immunology, oncology and other emerging disease areas. The IsoPlexis cellular response analysis platform was developed by scientific leaders at Yale and Cal Tech. By isolating single immune cells and analyzing their functional omic response, the platform can assess safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development and patient outcomes. Through collaborations with leading pharmaceutical companies and academic labs, the IsoPlexis technology is improving the targeting of breakthrough treatments. The venture capital-funded Yale spinout is headquartered in Branford, Connecticut. For additional information on IsoPlexis, visit http://www.isoplexis.com or email info@isoplexis.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/isoplexis-adds-infectious-disease-pioneer-dr-david-ho-to-its-scientific-advisory-board-300422907.html


'/>"/>
SOURCE IsoPlexis Corporation
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
2. Former Pfizer/Wyeth Global Infectious Disease Pharmaceutical Executive, Lewis Barrett, Appointed Senior Vice President, Commercial Strategy of Synthetic Biologics, Inc.
3. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Aspergillosis
4. Bavarian Nordic, the international novel cancer and infectious disease vaccines focused biotech, now covered by Edison.
5. Savara Pharmaceuticals Announces FDA Grant of Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Its Lead Product, AeroVanc
6. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis
7. Luminex Is Supporting U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in Research Efforts to Control African Ebola Outbreak
8. Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product
9. Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019
10. Edison Nation Medical Announces Open Innovation Search Focused on Preventing Spread and Transmission of Infectious Disease
11. Symbiotix Biotherapies Announces $2.3 Million Award from NIHs National Institute of Allergy and Infectious Diseases (NIAID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... , Aug. 11, 2017 DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... August 14 and host a conference call at 9:00am ... operating and financial results and its strategy and outlook ... hosted by Erez Raphael , Chief Executive Officer, ...
(Date:8/7/2017)... Insightin Health, provider of data-driven decision-making ... announced the selection of Michael Wood ... as of February 2017. In this role, Wood will ... our clients. Wood brings with him more than ... analytics within the healthcare industry. Wood formerly served ...
(Date:8/7/2017)... 7, 2017  Endo International plc (NASDAQ: ... resolve virtually all known U.S. mesh product liability claims ... the known remaining U.S. claims at reasonable values. Under ... the fourth quarter of 2017 and continuing through the ... quarter 2017 results, the Company intends to increase its ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance Group, a ... charity drive to generate community support for efforts to educate the local population on ... for all types of cancer. , Each day in America, roughly 4,600 new ...
(Date:8/18/2017)... ... August 18, 2017 , ... MLM Insurance ... serves communities throughout southern Florida, is working to support the Take Stock In ... from low income families. , The Take Stock In Children Foundation (TSC) offers ...
(Date:8/18/2017)... ... 18, 2017 , ... “Emotions are sacred, valid, honored, encouraged. This is the ... company Generation Mindful. To help change the mindset of parents and educators from punitive ... created the Time-In Toolkit, which launched on Kickstarter 3 weeks ago and fully funded ...
(Date:8/18/2017)... ... August 18, 2017 , ... Inc. magazine has ranked ... most prestigious ranking of the nation's fastest-growing private companies. This marks the eighth time ... Inc. 5000 ranking . This year’s ranking reflects ASH’s 76 percent overall revenue growth ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Three Narrow Roads”: a ... the creation of published author, Rev. Dr. Burnett King Sr., is currently the pastor-teacher-visionary ... founder of the Faith Track Club, Inc., a track-and-field program geared towards youth. , ...
Breaking Medicine News(10 mins):